Penn researchers in JAMA Network Open found new oral semaglutide starts briefly passed the injection in early March 2026. Tirzepatide stayed ahead the whole time.
Recap by typeshit. Full story at AJMC.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
7:35
A chiropractor's video looks at a pending FDA call he argues could affect timing and cost once retatrutide reaches the market.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Loading…